Discover
GERN
Geron Corporation
1.31
251 x 1.11
106 x 1.50
bid
ask
+
0.04
3.15%
01:19 PM
timesize
| Ytd | -0.76% | |
| 1y | -6.43% |
1.27
day range
1.31
1.04
52 week range
2.01
| Open | 1.29 | Prev Close | 1.27 | Low | 1.27 | High | 1.31 | Mkt Cap | 840.39M |
| Vol | 5.28M | Avg Vol | 15.38M | EPS | -0.11 | P/E | N/A | Forward P/E | 19.50 |
| Beta | 0.67 | Short Ratio | 4.30 | Inst. Own | 77.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 1.33 | 200-d Avg | 1.39 | 1yr Est | 3.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0 | N/A | 0.02 | 60.00% |
| 2026-02-25 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-06 | 2025-06 | 0 | N/A | 0.01 | 33.33% |
| 2025-05-07 | 2025-03 | 0 | N/A | 0.01 | 25.00% |
| 2025-02-26 | 2024-12 | 0 | N/A | -0.02 | -100.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-11-05 | Needham | Upgrade | Buy | Buy |
| 2025-05-08 | Scotiabank | Downgrade | Sector Outperform | Sector Perform |
| 2025-03-12 | Needham | Upgrade | Buy | Buy |
| 2025-03-12 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2025-02-27 | Scotiabank | Upgrade | Sector Outperform | Sector Outperform |
| 2025-02-27 | Stifel | Upgrade | Buy | Buy |
Profile
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-09 | FELLER FAYE | Officer | 0.00 | Sale |
| 2024-07-07 | GRETHLEIN ANDREW J | Chief Operating Officer | 0.00 | Sale |
| 2024-06-09 | KAPUR ANIL | Officer | 0.00 | Sale |
| 2025-05-08 | LAWLIS VIRGIL BRYAN JR. | Director | 13.30K | Purchase |
| 2026-02-17 | ROBERTSON MICHELLE | Chief Financial Officer | 17.65K | Sale |
| 2025-02-26 | SAMUELS SCOTT ALAN | Officer | 26.68K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | RA Capital Management, L.P. | 63.77M | 99.48M | 9.95% |
| 2025-12-30 | Blackrock Inc. | 45.91M | 71.62M | 7.16% |
| 2025-12-30 | Vanguard Group Inc | 35.66M | 55.63M | 5.56% |
| 2025-12-30 | Deep Track Capital, Lp | 32.51M | 50.72M | 5.07% |
| 2025-12-30 | Vivo Capital, LLC | 27.23M | 42.47M | 4.25% |
| 2025-12-30 | State Street Corporation | 26.87M | 41.91M | 4.19% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 20.05M | 31.29M | 3.13% |
| 2026-02-27 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 13.68M | 21.34M | 2.13% |
| 2026-01-30 | iShares Trust-iShares Russell 2000 ETF | 12.88M | 20.10M | 2.01% |
| 2026-01-30 | Vanguard Explorer Fund | 8.78M | 13.70M | 1.37% |
| 2026-02-27 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 6.49M | 10.13M | 1.01% |
| 2025-12-30 | abrdn Healthcare Investors | 6.25M | 9.75M | 0.98% |
Split
| Split | Date |
|---|---|
| 1058 : 1000 | 2014-07-22 |